Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00575757 · ClinicalTrials.gov registry record

Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV

A clinical trial, sponsored by Virginia Commonwealth University.

Completed
Registry status
12
Enrollment target

NCT00575757: Completed study, sponsored by Virginia Commonwealth University.

NCT00575757 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00575757 has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
12 participants
Enrollment target

Study Summary

Because NASH is now recognized as a significant cause of cirrhosis with associated morbidity and mortality, its recognition as a long term complication of HAART is important to the management of those living with HIV.

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2007-07
Est. Completion 2016-07
Virginia Commonwealth University

558 total trials

What the finished NCT00575757 record still lists

NCT00575757 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00575757 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00575757 about?

NCT00575757 is a clinical study titled "Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV". Because NASH is now recognized as a significant cause of cirrhosis with associated morbidity and mortality, its recognition as a long term complication of HAART is important to the management of those living with HIV.

What is the current status of trial NCT00575757?

This trial is currently completed. The enrollment target is 12 participants. The study started on 2007-07. Estimated completion is 2016-07.

Who is sponsoring clinical trial NCT00575757?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00575757, the US trial registry maintained by the National Library of Medicine. NCT00575757 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.